Media coverage about Enzymotec (NASDAQ:ENZY) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Enzymotec earned a coverage optimism score of 0.24 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.5551539118546 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
A number of research firms recently issued reports on ENZY. ValuEngine upgraded shares of Enzymotec from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. Wells Fargo & Company raised their target price on shares of Enzymotec from $9.50 to $12.00 and gave the company a “market perform” rating in a research note on Monday, October 30th. Jefferies Group LLC reiterated a “hold” rating and issued a $11.50 target price on shares of Enzymotec in a research note on Thursday, October 19th. Finally, Zacks Investment Research upgraded shares of Enzymotec from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 17th. Four analysts have rated the stock with a hold rating, The company currently has an average rating of “Hold” and a consensus target price of $11.75.
Shares of Enzymotec (NASDAQ:ENZY) remained flat at $$11.80 during trading on Monday. 15,600 shares of the company’s stock were exchanged, compared to its average volume of 63,772. Enzymotec has a 12 month low of $5.20 and a 12 month high of $12.35.
Enzymotec (NASDAQ:ENZY) last issued its quarterly earnings results on Wednesday, August 16th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.15). Enzymotec had a negative net margin of 14.52% and a negative return on equity of 3.88%. The company had revenue of $13.00 million during the quarter, compared to the consensus estimate of $12.78 million. During the same period last year, the company earned $0.04 earnings per share. Enzymotec’s revenue for the quarter was up 11.1% on a year-over-year basis. equities analysts anticipate that Enzymotec will post 0.01 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Enzymotec (ENZY) Earns Daily Media Sentiment Score of 0.24” was published by Markets Daily and is the property of of Markets Daily. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.themarketsdaily.com/2017/11/14/enzymotec-enzy-earns-daily-media-sentiment-score-of-0-24.html.
Enzymotec Company Profile
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.